TianTi Bio opens new doors for therapeutic discovery

We provide deep mining of the entire natural immune repertoire at unprecedented scale and sensitivity resulting in greater scientific success.

Next Generation Technology

TianTi Biotherapeutics' AbLink™, OptAb™ and Rapid VHH technology platforms significantly improve hit success rates. These technologies are engineered to deliver fast, high-quality results for challenging targets. Together they generate greater numbers of differentiated antibodies while also providing a strong basis for intellectual property protection.

Leveraging Natural Selection to Your Advantage

The best resource for antibodies with therapeutic potential is nature. In nature, the generation of antibodies in vivo is a complex process that has been diversified and optimized over hundreds of millions of years. Multiple IGHV, IGLV, and IGKV germline genes, each encoding two antigen binding loops, hypervariable in sequence and structure, are available for the generation of antibodies.

LEARN MORE

Antibodies attack a cancer cell or virus 3d illustration

Tianti Biotherapeutics' Offerings

AbLink™ Advantage

Comprehensively screen the natural antibodies repertoire
Extensive epitope coverage
Increased unique and rare clones resulting in greater diversity
High affinity and functionality
Hit validation without need of mammalian cells

OptAb™ Advantage

De novo library design leveraging public algorithms and in-house expertise
Large library screening increases success potential
Three-in-one benefit: simultaneous humanization, optimization, and affinity maturation

Rapid VHH Advantage

High quality VHH antibody discovery
Yeast engineering that expresses VHH at the highest levels
VHH library construction directly captures the natural diversity of Llama and Alpaca immune response
Customized selection strategies rapidly isolate desired VHH hits saving time and effort

Researching diseases with limited options is challenging.
We provide new possibilities.